KYORIN Pharmaceutical Co., Ltd.

PickUp

These websites are only available in Japanese.

News Releases

November 8, 2023: Summary of Consolidated Financial Results(For second quarter ended September 30, 2023) [Japanese GAAP]
November 8, 2023: Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2024 (Nov 8, 2022) - Supplementary Information
November 8, 2023: Notice of differences between Forecasts and Actual Results
September 29, 2023: Notice Regarding Implementation of voluntary Retirement Program
August 2, 2023: Summary of Consolidated Financial Results(For the first quarter ended June 30, 2023) [Japanese GAAP]

About Kyorin

KYORIN Holdings, Inc. has merged its wholly owned subsidiary KYORIN Pharmaceutical. Co., Ltd and has changed its trade name to “KYORIN Pharmaceutical. Co., Ltd.” on April 2023.

More detail

Investor Relations

This section provides information on the medium-term business plan, pipeline, IR library and stock.

More detail

Sustainability

Following our corperate philosophy, Kyorin Group is working to contribute to society’s continuous development and our sustainable growth by fulfilling our social responsibility through we business activities with new drug as our core business.

More detail

R&D

A large number of unmet medical needs are still present in the world. This section provides information on our initiatives for drug discovery, and development pipeline.

More detail

PickUp

News Releases

Contens

About Kyorin

Investor Relations

Sustainability

R&D

Kyorin Group